Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AVID200
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Acquisition
Bristol Myers Squibb Completes Acquisition of Forbius
Details : Pursuant to the terms of the transaction, Forbius’ non-TGF-beta assets were transferred to a newly formed private company which is being retained by Forbius’ existing shareholders.
Brand Name : AVID200
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 21, 2020
Lead Product(s) : AVID200
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : AVID200
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Acquisition
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio
Details : Under this transaction, Bristol Myers Squibb would acquire Forbius’s TGF-beta program, including the program’s lead investigational asset, AVID200. TGF-beta is a key cytokine that regulates various cell processes, including regulation of the immune s...
Brand Name : AVID200
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 24, 2020
Lead Product(s) : AVID200
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?